Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) are rare neurodegenerative disorders with limited treatment options and poor prognoses. Congressional attention to research funding could accelerate therapeutic development for conditions that currently offer patients few evidence-based interventions.
CurePSP organized a bipartisan congressional briefing to advocate for increased research funding into three rare neurodegenerative conditions: progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy. These disorders, collectively affecting fewer than 50,000 Americans, involve tau protein accumulation and alpha-synuclein pathology respectively. Current treatment remains largely symptomatic and supportive, with no disease-modifying therapies available. The briefing aimed to raise awareness of these conditions’ unmet medical needs and advocate for enhanced federal research investment.
“While cannabis advocates often co-opt ‘CBD’ terminology, this briefing addresses corticobasal degeneration — a devastating neurological condition with zero relationship to cannabidiol. Patients with these rare disorders deserve research funding based on medical need, not acronym confusion.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
FAQ
What type of medical conditions does this research focus on?
This research focuses on neurodegenerative diseases, movement disorders, and rare diseases. These are complex medical conditions that often require specialized treatment approaches and ongoing research.
What is the clinical relevance rating for this study?
This study has received a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This means the findings represent emerging developments that are worth monitoring closely by healthcare professionals.
Yes, this appears to be cannabis research that has research funding support. The funding likely enables further investigation into cannabis applications for the specified medical conditions.
Why is this research considered noteworthy?
The research is considered noteworthy because it represents emerging findings or policy developments in cannabis medicine. It specifically addresses rare and complex neurological conditions that have limited treatment options.
What should clinicians know about this development?
Clinicians should monitor this research closely as it may lead to new treatment options for patients with neurodegenerative and movement disorders. The findings could potentially influence future clinical practice and treatment protocols.